For an ageing population without enough neurologists to see everyone at risk, a 20-minute EEG cap that says whether a patient’s cognitive function is impaired is a triage tool. On 19 August 2026, China’s National Medical Products Administration approved such a device, made by Tianjin-based Tiankai Suishi Intelligent Technology, for cognitive-impairment assessment. The clearance sits inside China’s non-invasive diagnostic tier of brain-computer interface devices, not the invasive commercial category cleared for Neuracle’s implantable BCI in March 2026.
What was cleared
The Tiankai Suishi device is a non-invasive scalp EEG cap that reads brain electrical signals and produces an assessment of whether cognitive function is impaired. The company’s product roster extends to early-diagnosis devices for Alzheimer’s disease and schizophrenia-linked cognitive dysfunction. A depression-diagnosis product has been separately filed with NMPA and is pending clearance.
The approval sits in the diagnostic-device tier: Class II non-invasive, distinct from the Class III invasive category. Neuracle’s March 2026 NMPA approval remains China’s flagship commercial invasive BCI clearance. Tiankai Suishi’s device does not compete with implantable systems for paralysis restoration or motor rehabilitation, and does not overlap with the Neuralink N1 category. It sits alongside consumer-grade EEG wearables at the diagnostic-cap level but with regulatory-grade indications: dementia, psychiatric-adjacent cognitive dysfunction, and depression.
The company
Tiankai Suishi Intelligent Technology was founded in 2023 in Tianjin. Registered capital is RMB 10.67 million, roughly US$1.59 million. The company is led by Gu Bin, who holds a medical doctorate from Tianjin University. Public disclosure does not include a lifetime funding total, most recent priced round, named investors, or revenue baseline. The company’s product pipeline extends beyond the approved cognitive-assessment cap into depression diagnosis (NMPA filing pending) and Alzheimer’s and schizophrenia early-diagnosis devices.
Where it fits in China’s 2026 BCI approval flow
Neuracle’s March 2026 NMPA approval was a Class III invasive-BCI landmark: the world’s first commercial invasive BCI clearance. Tiankai Suishi’s August 2026 clearance sits one regulatory tier down, in Class II non-invasive diagnostics, and one clinical tier over, in early-detection of neurodegenerative and psychiatric-adjacent conditions rather than in motor or communication restoration.
Read together, the pattern from March through August is that China’s Industrial Builder posture is widening. The country has one commercial invasive BCI cleared (Neuracle), one commercial non-invasive diagnostic BCI cleared (Tiankai Suishi), a state-industrial capital layer running through the MIIT 15th Five-Year Plan naming BCIs as a future industry (26 August 2026), and a growing cohort of named BCI operators including StairMed, NeuroXess, NeuCyber, Weiling Medical, and BrainCo. The diagnostic-device tier is where the largest volume of approvals is likely to sit over the next 24 months. Non-invasive Class II clearances face a shorter regulatory path than invasive Class III implantables and address indications with immediate public-health scale in a population of over 1.4 billion.
The indications match China’s ageing-population health pressures
Tiankai Suishi’s cognitive-impairment assessment cap targets Alzheimer’s disease and psychiatric-adjacent cognitive dysfunction. A depression-diagnosis product is pending. These are the same indications driving Chinese state investment in neurotechnology: a rapidly ageing population, rising dementia prevalence, and a national mental-health infrastructure that is still under-resourced against demand.
The strategic read is that non-invasive diagnostic BCI in China is not being commercialised as a Neuralink competitor. It is being commercialised as ageing-population diagnostic infrastructure, at a price and volume point a Class II non-invasive cap can support and a Class III invasive implant cannot.
Not disclosed
Tiankai Suishi’s lifetime funding, most recent priced round, and named investors are not disclosed. The unit price of the cleared device is not disclosed. The specific NMPA registration number and pathway classification (whether standard Class II or an accelerated pathway) are not disclosed. The clinical evidence base cited by NMPA for the cognitive-impairment indication is not disclosed. The depression-diagnosis product’s NMPA filing date and expected clearance window are not disclosed. Distribution partners in the Chinese hospital and community-clinic channels are not disclosed. Whether Tiankai Suishi has any export ambitions beyond the Chinese market is not disclosed.
What to watch
Whether NMPA clears the Tiankai Suishi depression-diagnosis product in the coming quarters. A second Class II clearance from the same company would establish Tiankai Suishi as a multi-indication diagnostic-BCI operator rather than a single-product startup.
Whether other Chinese Class II non-invasive diagnostic-BCI clearances land in the September to December 2026 window. A cluster of clearances would confirm that NMPA is running a diagnostic-tier pipeline in parallel with the Class III invasive-BCI track that Neuracle opened.
Whether any of Tiankai Suishi’s competitors in the non-invasive Chinese cohort (including operators tied to Tsinghua, Tianjin University, and the Shanghai-Zhejiang academic-industrial corridor) file for equivalent cognitive-assessment clearances. A category race, rather than a single-company approval, is what would move Chinese non-invasive diagnostic BCI from an isolated regulatory event into a defined commercial category.
Whether Tiankai Suishi raises a priced round on the back of the August approval. The registered capital of RMB 10.67 million is small-startup scale. An institutional round would signal that Chinese venture capital is willing to fund the diagnostic-BCI tier as a distinct category from the invasive-BCI tier.
Whether the ADI Neuroscience US$1 billion India neurotech fund announced on 28 August 2026 or other Asia-facing capital vehicles disclose interest in the diagnostic-BCI tier. If diagnostic BCI attracts capital at scale across Asia, the category becomes a competitive layer of its own rather than a sub-track of the invasive-BCI race.